Caffeine is the single most widely consumed behaviorally-active substance in the world. In the United States, estimated per capita intake of caffeine approaches an average of 200 mg daily, mainly from dietary sources. Despite these statistics there have been surprisingly few studies of the behavioral consequences of chronic caffeine intake. Daily administration of caffeine results in tolerance to behavioral actions of the drug and perhaps physical dependence as well, facts not generally appreciated. Experiments are proposed to continue and expand upon ongoing research directed toward defining tolerance to behavioral effects of caffeine. Behavioral changes will be correlated with changes in brain neurotransmitter systems (e.g., adrenergic and adenosine) that have ben implicated in actions of caffeine in order to determine molecular mechanisms of drug action. Most studies will be performed on rats receiving scheduled-access to water bottles containing caffeine solution, and consuming approximately 70 mg/kg/day of drug. Matched controls will receive scheduled- access to drug-free tap water. Behavioral variables will include locomotor activity, food-reinforced schedule-controlled behavior, and drug discrimination. Temporal and pharmacologic parameters of caffeine tolerance will be determined, such as rate of development, surmountability, and cross-tolerance or otherwise altered sensitivity to various prototypic drugs. In order to begin examining the generality of findings in the rat, observations on caffeine effects on locomotor activity and drug discrimination will be extended to a primate species, the squirrel monkey. Experiments will be performed to determine the direct effects of caffeine on responses mediated by noradrenergic receptors (e.g., production of inositol phosphates) and on tyrosine hydroxylase activity on rat brain tissue in vitro. in addition, neurochemical parameters in discrete areas of rat brain will be correlated with behavioral changes in rats during caffeine tolerance and withdrawal. These parameters will include density and responsiveness of adenosine receptors, responsiveness of adrenergic receptors to norepinephrine, tyrosine hydroxylase activity in noradrenergic and dopaminergic neurotransmitter systems, and potassium-stimulated release of catecholamines.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003413-07
Application #
3207903
Study Section
Drug Abuse Clinical and Behavioral Research Review Committee (DACB)
Project Start
1984-07-01
Project End
1992-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Emory University
Department
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Jain, Raka; Holtzman, Stephen G (2005) Caffeine induces differential cross tolerance to the amphetamine-like discriminative stimulus effects of dopaminergic agonists. Brain Res Bull 65:415-21
Powell, K R; Iuvone, P M; Holtzman, S G (2001) The role of dopamine in the locomotor stimulant effects and tolerance to these effects of caffeine. Pharmacol Biochem Behav 69:59-70
Holtzman, S G (1999) Discriminative effects of CGS 15943, a competitive adenosine receptor antagonist, have a dopamine component in monkeys. Eur J Pharmacol 376:7-15
Powell, K R; Holtzman, S G (1998) Lack of NMDA receptor involvement in caffeine-induced locomotor stimulation and tolerance in rats. Pharmacol Biochem Behav 59:433-8
Easterling, K W; Holtzman, S G (1997) Parametric changes in response equilibrium during an intra-cranial self stimulation (ICSS) task: can reward value be assessed independently of absolute threshold? Neurosci Biobehav Rev 21:55-65
Garrett, B E; Holtzman, S G (1996) Comparison of the effects of prototypical behavioral stimulants on locomotor activity and rotational behavior in rats. Pharmacol Biochem Behav 54:469-77
(1996) Caffeine: a model drug of abuse. NIDA Res Monogr 162:73-5
Holtzman, S G (1996) Discriminative effects of CGS 15943, a competitive adenosine receptor antagonist, in monkeys: comparison to methylxanthines. J Pharmacol Exp Ther 277:739-46
Garrett, B E; Holtzman, S G (1995) Does adenosine receptor blockade mediate caffeine-induced rotational behavior? J Pharmacol Exp Ther 274:207-14
Garrett, B E; Holtzman, S G (1994) Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction. Eur J Pharmacol 262:65-75

Showing the most recent 10 out of 32 publications